An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPA

niversity College London0 个研究点目标入组 11 人开始时间: 2016年8月5日最近更新: 2021年10月8日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 11

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1.Age at screening = 4 and = 18 years
•2.Children to be included must fulfil the new EULAR/PRINTO/PReS classification criteria for childhood systemic PAN (4) as defined by:
•Histopathological evidence of necrotising vasculitis in medium- or small-sized arteries or angiographic abnormality as a mandatory criterion (4); plus one of the following five:
•i.skin involvement
•ii.myalgia or muscle tenderness
•iii.hypertension
•iv.peripheral neuropathy
•v.renal involvement
•3.Newly diagnosed* and with active disease that would normally require treatment with CYC:
•i.One or more of major PVAS items (see below)
•ii.and / or three or more minor PVAS items,
•iii.and/or either of the two additional entry criteria:
•1.Severe systemic inflammation and/or features of macrophage activation syndrome due to PAN where the investigator would routinely use cyclophosphamide
•2.Demonstration of severe angiographic changes consistent with systemic PAN with other compatible clinical features, but not necessarily including the major PVAS items listed above
•4.Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding.
•Sufficient disease activity for trial entry (see inclusion criteria 3 above) requires at least one major or 3 minor PVAS items as listed below, and/or at least one of the additional criteria listed in the following section.
•Major PVAS items (indicated in bold in the PVAS form):
•Trial entry criteria or major relapse require the recurrence or new appearance of major organ involvement, if they are attributable to active vasculitis:
•1.Severe cutaneous vasculitis: significant infarct, ulcer or gangrene. Other significant cutaneous vasculitis such as widespread bullous vasculitic skin disease would also be an inclusion criterion.
•2.Threatened vision from any of: retinal vasculitis, retinal vessel thrombosis, scleritis, retinal exudates, or retinal haemorrhages.
•3.Major chest involvement: major pulmonary bleeding, with shifting pulmonary infiltrates; other causes of bleeding should be excluded if possible.
•4.Cardiovascular involvement: loss of pulses, bruits over accessible arteries, blood pressure discrepancy more than 10 mmHg in any limb, claudication of extremities, ischaemic cardiac pain, cardiomyopathy, congestive cardiac failure, valvular heart disease, pericarditis.
•5.Abdominal involvement: abdominal pain, blood in stools or bloody diarrhoea, or bowel ischaemia. Pancreatitis, whilst not specifically listed as a PVAS item, would also be an indication for inclusion.
•6.Renal involvement: hypertension, significant proteinuria, significant haematuria (if microscopic haematuria > 5 red blood cells per high power field, or red cell casts), GFR < 80 mls/min/1.73m2 , rise in creatinine > 10% or creatinine clearance (GFR) fall > 25%. Biopsy is strongly recommended for recurrent haematuria or unexplained rise in creatinine EXCEPT where large renal arterial aneurysms have been demonstrated.
•7.Nervous system involvement: meningitis or encephalitis, organic confusion /cognitive dysfunction, non-hypertensive seizures, stroke, cord lesion, cranial nerve palsy, sensory peripheral neuropathy, or motor mononeuritis multiplex. (Imaging of brain/cord providing supportive evidence that these lesions are due to vasculitis are usually present for those items pertaining to the brain or cord).
•Minor PVAS items:
•Minor entry criteri

排除标准

•Exclusions related to vasculitis type and/ or severity
•1.Diagnosis of alternative vasculitic syndrome e.g. HSP, or ANCA vasculitis
•2.Patients requiring dialysis
•Exclusions related to general health
•3.Evidence of other significant uncontrolled concomitant disease that in the investigator’s view would preclude or interfere with patient participation. This will be recorded in the screening log.
•4.Primary or secondary immunodeficiency including known history of human immunodeficiency virus (HIV) infection
•5.Known active and/or chronic infection of any kind (excluding fungal nail and/or minor fungal skin infections)
•6.History of serious recurrent or chronic infection including tuberculosis (a screening chest radiograph will be performed if not performed within 12 weeks prior to randomisation)
•7.History of cancer, including solid tumours, haematologic malignancies and carcinoma in situ
•8.Participation in a clinical trial testing a medicinal product within 3 months (12 weeks) preceding randomisation for the MYPAN trial.
•Exclusions related to medications
•9.History of a severe allergic or anaphylactic reaction to any of the study medications or their excipients
•10.More than 3g of IV methylprednisolone within one month (4 weeks) prior to randomisation
•11.More than 3 weeks of oral prednisolone/prednisone at dose of 2mg/Kg once daily within one month (4 weeks) prior to randomisation
•12.Treatment with MMF or azathioprine for more than two weeks; or more than one intravenous dose of cyclophosphamide (>500 mg/m2) within one month (4 weeks) prior to randomisation
•13.Rituximab or high dose intravenous immunoglobulin within the last twelve months (48 weeks)
•14.Intolerance or contraindications to intravenous glucocorticoids
•15.Participant of reproductive potential not prepared to use a reliable means of contraception (e.g. hormonal contraceptive patch, intrauterine device, physical barrier) throughout study participation;
•a.Sexually active female not prepared to use two reliable forms of contraception for the complete duration of the trial
•Exclusions related to laboratory findings
•16.Positive urine human chorionic gonadotropin (hCG) measured at screening / (if appropriate) or a positive urine pregnancy test prior to study entry or breastfeeding
•17.Positive tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C serology at randomisation
•18.Absolute neutrophil count <1.5 x 109/l
•19.Estimated GFR <15 mL/min/1.73m2 (calculated using the Schwartz GFR formula – See section 7.4.2 for formula) at randomisation

研究者

发起方

niversity College London

相似试验

已完成

不适用

An open-label randomized controlled trial of ampicillin/cloxacillin and ceftriaxone for empirical treatment of infective endocarditisInfective endocarditis

JPRN-UMIN000032006Juntendo University30

已完成

不适用

A randomized open-label prospective trial for comparing combination therapy Peg-Interferon alfa-2a (PEGASYS®) and Adefovir dipivoxil (Hepsera®) and combination therapy Peg-Interferon alfa-2a (PEGASYS®) and Tenofovir disoproxil fumarate (Viread®) versus no treatment in HBeAg negative chronic hepatitis B patients with low viral load*viral hepatitis1001965410047438chronic hepatitis B

NL-OMON32978Academisch Medisch Centrum150

已完成

2 期

Bowel disorder and its homoeopathic treatment

CTRI/2017/05/008480ational Institute of Homoeopathy Ministry of AYUSH Govt of India60

进行中（未招募）

不适用

A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.

EUCTR2005-000594-22-BETibotec Pharmaceuticals Limited500

进行中（未招募）

1 期

A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects.

EUCTR2005-000594-22-GBTibotec Pharmaceuticals Limited